A pilot agreement with Abbott advances Ainnova's commercial and clinical footprint.
As part of its ongoing commercial expansion, Ainnova Tech entered into a pilot agreement with Abbott, a global leader in medical devices and diagnostics. The collaboration was disclosed within Ainnova's corporate filings.
Pilots like this one allow Ainnova to validate its VisionAI platform and broader portfolio alongside established healthcare partners, accelerating the path from screening to timely diagnosis.
Abbott is a global healthcare leader that helps people live fully at all stages of life. Its portfolio spans diagnostics, medical devices, nutrition and branded generic medicines — including widely used diabetes-care technologies such as continuous glucose monitoring.
Abbott serves people in more than 160 countries worldwide.
Ainnova Tech is a healthcare technology company focused on revolutionizing early disease detection using artificial intelligence. Its platform, VisionAI, analyzes retinal images to detect early markers of diseases such as diabetic retinopathy — with a growing portfolio spanning cardiovascular, metabolic, liver and kidney risk. Ainnova is dedicated to making healthcare more proactive, accessible and efficient.
Source: Corporate filing ↗
Contact: Ainnova Tech — info@ainnovatech.com